Volume 22, Number 6—June 2016
Dispatch
Prospective Validation of Cessation of Contact Precautions for Extended-Spectrum β-Lactamase–Producing Escherichia coli1
, Reno Frei, Friedbert Schwahn, Milanka Tomic, Martin Conzelmann, Anne Stranden, and Andreas F. Widmer
Table
Characteristics and exposures for hospitalized contact patients with and without transmission of ESBL-producing Escherichia coli from index patients, Basel, Switzerland*
| Patient characteristics and exposures | Contact patients with transmission of ESBL-producing E. coli, n = 11† | Contact patients without transmission of ESBL-producing E. coli, n = 220† | p value |
|---|---|---|---|
| Contact patient characteristics | |||
| Age, y, median (IQR) | 81 (77–82) | 75 (64–82) | 0.153 |
| Charlson Comorbidity Index, median (IQR) | 2 (1–4) | 2 (1–3) | 0.399 |
| Contact time, d, median (IQR) | 13 (10–15) | 8 (5–12) | 0.006 |
| Intensive care unit stay | 0 | 54 (24.8) | 0.122 |
| Received any antimicrobial drug | 4 (36.4) | 93 (42.3) | 0.765 |
| Received systemic antimicrobial drugs with activity against ESBL E. coli |
1 (9.1) |
19 (8.6) |
1.000 |
| Index patient characteristics | |||
| Age of index patient, y, median (IQR) | 79 (64–87) | 73 (62–80) | 0.175 |
| Charlson Comorbidity Index, median (IQR) | 2 (1–3) | 2 (1–3) | 0.572 |
| Infected with ESBL-producing E. coli | 6 (54.6) | 84 (38.2) | 0.346 |
| ESBL-producing E. coli infection | |||
| Bloodstream | 0 | 3 (1.4)‡ | 1.000 |
| Urinary tract | 5 (45.5) | 68 (30.9) | 0.330 |
| Respiratory tract | 1 (9.1) | 10 (4.6) | 0.422 |
| Surgical site | 0 | 6 (2.7) | 1.000 |
| Colonized with ESBL E. coli | 5 (45.4) | 136 (61.8) | 0.346 |
| Received systemic antimicrobial drugs with activity against ESBL E. coli | 6 (54.6) | 84 (38.2) | 0.346 |
*Bold indicates significance. Contact patient exposures occurred through the sharing of a room for at least 24 hours with an ESBL-producing E. coli–infected or colonized index patient in an acute-care hospital or a geriatric/rehabilitation center. ESBL, extended-spectrum β-lactamase; IQR, interquartile range.
†Values are no. (%) patients except as indicated.
‡All patients with bloodstream infections had urinary tract infections.
1Preliminary results from this study were presented at the 25th European Congress of Clinical Microbiology and Infectious Diseases; April 25–28, 2015; Copenhagen, Denmark.